Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Search content at Mayo Clinic
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
Raoul Tibes
, James M. Bogenberger
, Holly L. Geyer
, Ruben A. Mesa
Hematology/Oncology
Hospital Internal Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
15
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'JAK2 inhibitors in the treatment of myeloproliferative neoplasms'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myeloproliferative Neoplasms
100%
JAK2 Inhibitor
100%
JAK-STAT Pathway
75%
Janus Kinase 2 (JAK2)
37%
Growth Factors
25%
Therapeutic Intervention
12%
Novel Therapeutics
12%
Molecular Events
12%
Targeted Agents
12%
Vulnerability
12%
Dysregulation
12%
Pathway Activation
12%
Lymphocytes
12%
Negative Regulator
12%
Clinical Characteristics
12%
Selective Inhibitor
12%
JAK-STAT
12%
Molecular Aberrations
12%
Adapter Protein
12%
Epigenetic Dysregulation
12%
Clinical Trial Results
12%
Rational Therapy
12%
JAK2V617F
12%
JAK2V617F mutation
12%
Expert Opinion
12%
Area Cover
12%
JAK Inhibition
12%
JAK Inhibitors
12%
Mutation Specific
12%
Parallel Pathways
12%
SOCS1
12%
Thrombopoietin Receptor
12%
SH2B3
12%
MPL mutation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloproliferative Neoplasm
100%
Janus Kinase 2 Inhibitor
100%
JAK-STAT Signaling
75%
Janus Kinase
37%
Growth Factor
25%
Cytokine
25%
Phosphotransferase
12%
Combination Therapy
12%
Janus Kinase Inhibitor
12%
Clinical Trial Results
12%
Thrombopoietin Receptor
12%
Suppressor of Cytokine Signaling
12%